Ceapro Inc V.CZO

The big one...

[prophetoffactz]

"Further, over the past quarter we remained very active with strategic corporate initiatives aimed towards achieving a stated objective related to uplisting Ceapro to an international stock exchange." news release

The company continues to be "very active" towards the objective of listing on NASDAQ.
Such an event could put a value on CZO's pipeline with the avenanthramide clinical trial about to dose its first patients, the 5X PGX scale-up expected to be completed by the end of the year and commissioned in Q1 2024, and with the comapny closing in on a clinical trial decision for the fibrosis product which Dr. Martin Kolb has said could profoundly change the landscape for fibrosis treatment if preclinical results are replicated. Reordering from CZO's major customer could also be near as CZO and Symrise also word towards the launch of dry powder formulations of avenanthramide and oat beta glucan which could expand the market. The Angiogenesis Foundation is also working towards completing its research on wound healing opening the door to a potential partnership deal. The avenanthramide malted techology is also advancing as CZO further has designed a an animal model protocol to test the immune stimulating properties of PGX-YBG vs. the competition. 

DO we take this to mean it's only a matter of time before Kenvue, CZO's major client, returns? 

• Developed powder formulation of high avenanthramides concentration for enriched skin formulations. Of note, Ceapro’s partner Symrise relaunched under a solid form an avenanthramide derivative product that they had marketed for almost two decades. While this relaunched analog is a byproduct from another oat-based extracted product not sold by Ceapro, it is produced in very small volumes and does not compete with Ceapro’s products nor with Symrise-Ceapro exclusive customers. However, the relaunch of this product by Symrise might be a proof of concept demonstrating an appetite from the cosmeceutical market to use powder formulations. Symrise and Ceapro are jointly assessing such potential opportunities.

[lscfa]

I suspect the legal fees incurred are really for Nasdaq lisitng nonsense and nothing to do with DD on market opportunities.

[prophetoffactz]

Listing on NASDAQ could put a price tag on CZO's pipeline as the pipeline also reached key valuation milestones from PGX scale-up and licensing, to the first human clinical data for the avenanthramide pill, and a clincal trial decision for PGX-YBG/fibrosis. The wound healing study with the Angiogenesis Foundation also opens the door to a potential partnership.  CZO wouldn't be

[prophetoffactz]

An intention to list on NASDAQ would appear to speak about the confidence in coming milestones; including PGX scale-up and potential licensing. CZO is going into a series of expected valuation catalysts evaluating how it gets on the biggest stage. The avenanthramide pill results could start flowing fast also and Avalyn raised C$80 million cash going into its Phase I clinical fibrosis trial. 

[Tencents]

No mention of qtr backlog of sales being caught up Guess it's not going to happen despite indications in prior qtr releases 

[prophetoffactz]

Last quarter CZO thought it was lagging the previous year's revenue by one quarter. With the quarter announced today it is lagging 2 quarters. Given we are two months into Q3 and they didn't announce re-ordering had re-commenced it looks like they are now lagging at least three quarters. If no reordering in Q1 2024 that would be one year lagging. Did Kenvue have twice as much inventory

[lscfa]

Mgmt is not savvy enough for Nasdaq sharks. e.g. co. should have highlighted one-time expenses that will not recur like $921,000 in legal fees.

[PBaelishh]

Agreed. Gagnon - and his CFO - are terrible with the statement Notes.  Notes are supposed to qualify, NOT placate, obfuscate. I think Grant Thornton, the auditors, are not doing their job either... this all smells of rubber-stamping as opposed to interogating.

[prophetoffactz]

"e.g. co. should have highlighted one-time expenses that will not recur like $921,000 in legal fees." News release: "Continued to assess possible corporate strategies to support the accelerated growth of the Company along with stated objective of uplisting to Nasdaq." "...over the past quarter we remained very active with strategic corporate initiatives aimed